XTL Biopharmaceuticals Ltd ADR XTLB

Morningstar Rating
$1.55 +0.07 (4.73%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

XTLB is trading at a LOCK|>><r< premium.
Price
$1.48
Fair Value
LOCK|&fbVh?b
Uncertainty
LOCK|m$ rs&@B
1-Star Price
LOCK|?^jz<jw
5-Star Price
LOCK|$^?Bx?
Economic Moat
LOCK|nTgl
Capital Allocation
—

Trading Information

Previous Close Price
$1.48
Day Range
$1.55–1.59
52-Week Range
$0.00–5.64
Bid/Ask
$1.25 / $1.60
Shares Outstanding
2.46M
Market Cap
$3.81M
Volume/Avg
1,231 / 7,069

Key Statistics

Price/Earnings (Normalized)
0.67
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
5

Valuation

Metric
XTLB
Price/Earnings (Normalized)
0.67
Price/Book Value
—
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
XTLB

Financial Strength

Metric
XTLB
Quick Ratio
0.34
Current Ratio
0.40
Interest Coverage
−116.00
Quick Ratio
XTLB

Profitability

Metric
XTLB
Return on Assets (Normalized)
166.10%
Return on Equity (Normalized)
305.08%
Return on Invested Capital (Normalized)
275.53%
Return on Assets
XTLB

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|Nq#S&k!LOCK|#ss^$132B
Regeneron Pharmaceuticals Inc
REGN
LOCK|>k&?QxLOCK|>hRGw$96B
Moderna Inc
MRNA
LOCK|<HSZD?LOCK|G&&$81B
argenx SE ADR
ARGX
LOCK|$%xDFQLOCK|B<$59B
BeOne Medicines Ltd ADR
ONC
LOCK|T&MhPfLOCK|$Z>$47B
Royalty Pharma PLC Class A
RPRX
LOCK|<?#l$@gNLOCK|Vp%#%$30B
Incyte Corp
INCY
LOCK|@CsGy#LOCK|&<l$24B
BioNTech SE ADR
BNTX
LOCK|d!?xhc^LOCK|^N@$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|JXQ&MZ<LOCK|sMHcW$20B
BridgeBio Pharma Inc
BBIO
LOCK|&#k!fjqLOCK|t>m$15B

Sponsor Center